Current Value
$47.201 Year Return
Current Value
$47.201 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DXCM | -23.51% | $32.84B | -24.43% | 0.00% |
SPNS | -20.61% | $1.65B | -14.78% | 1.96% |
MNDY | -15.87% | $15.53B | +28.69% | 0.00% |
CRDO | -13.23% | $16.02B | +196.95% | 0.00% |
WRLD | -13.16% | $916.41M | +36.51% | 0.00% |
KGC | -12.59% | $18.64B | +76.83% | 0.79% |
OR | -12.23% | $4.84B | +62.23% | 0.75% |
NVDA | -11.90% | $3.90T | +21.78% | 0.02% |
VERX | -11.80% | $5.73B | +0.67% | 0.00% |
STRL | -11.60% | $6.90B | +104.38% | 0.00% |
BNED | -11.47% | $407.62M | +62.64% | 0.00% |
FF | -11.18% | $179.59M | -16.50% | 5.80% |
PSN | -10.77% | $8.00B | -4.15% | 0.00% |
AXON | -10.63% | $61.52B | +164.72% | 0.00% |
TASK | -10.61% | $1.50B | +18.87% | 0.00% |
NGD | -10.36% | $3.75B | +110.67% | 0.00% |
RLX | -10.35% | $2.07B | +25.27% | 0.44% |
IAG | -10.03% | $3.96B | +69.29% | 0.00% |
QNRX | -9.75% | $5.13M | -58.29% | 0.00% |
AEM | -9.71% | $58.71B | +65.44% | 1.38% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GCC | 0.04% | $140.53M | 0.55% |
CLSE | 0.07% | $187.53M | 1.44% |
IBND | -0.07% | $410.99M | 0.5% |
ARGT | -0.10% | $1.03B | 0.59% |
IBDQ | -0.11% | $2.96B | 0.1% |
YMAG | -0.15% | $362.17M | 1.12% |
SLV | -0.16% | $17.63B | 0.5% |
IZRL | 0.17% | $119.68M | 0.49% |
IYW | 0.22% | $21.95B | 0.39% |
XHLF | -0.23% | $1.73B | 0.03% |
KRBN | -0.28% | $162.57M | 0.85% |
STPZ | -0.28% | $443.02M | 0.2% |
BIL | 0.39% | $41.97B | 0.1356% |
COM | 0.39% | $209.85M | 0.72% |
IBD | 0.40% | $389.24M | 0.43% |
SIVR | -0.48% | $2.03B | 0.3% |
FEMB | -0.48% | $210.90M | 0.85% |
CERY | 0.54% | $480.87M | 0.28% |
MAGS | -0.57% | $2.36B | 0.29% |
FBCG | 0.71% | $4.44B | 0.59% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PPH | 51.54% | $589.08M | 0.36% |
SPHD | 50.60% | $3.23B | 0.3% |
IHE | 49.46% | $559.80M | 0.39% |
SCHD | 48.09% | $71.26B | 0.06% |
XLV | 47.42% | $34.49B | 0.09% |
DHS | 47.40% | $1.26B | 0.38% |
IYH | 46.87% | $2.74B | 0.39% |
FHLC | 46.80% | $2.45B | 0.084% |
VHT | 46.46% | $15.43B | 0.09% |
IXJ | 46.39% | $3.76B | 0.41% |
LVHD | 46.38% | $571.73M | 0.27% |
FDL | 46.28% | $5.59B | 0.43% |
SPYD | 45.48% | $6.99B | 0.07% |
HDV | 45.45% | $11.20B | 0.08% |
XPH | 45.03% | $150.90M | 0.35% |
RSPH | 44.85% | $726.61M | 0.4% |
SDOG | 44.81% | $1.22B | 0.36% |
PEY | 43.79% | $1.15B | 0.53% |
CDC | 43.66% | $750.81M | 0.42% |
BBH | 43.39% | $340.09M | 0.35% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PFE | 52.61% | $145.66B | -7.58% | 6.64% |
GILD | 44.41% | $138.15B | +63.90% | 2.79% |
MMM | 43.43% | $82.74B | +54.22% | 1.86% |
JNJ | 42.58% | $374.84B | +5.94% | 3.23% |
AMGN | 42.24% | $159.70B | -5.99% | 3.11% |
DOC | 41.39% | $12.65B | -7.28% | 6.63% |
TMO | 41.19% | $160.88B | -19.87% | 0.39% |
GSK | 40.53% | $77.84B | -0.31% | 4.15% |
FLO | 39.79% | $3.33B | -26.73% | 6.13% |
AVTR | 39.33% | $9.37B | -34.15% | 0.00% |
MKC | 37.77% | $19.56B | +4.04% | 3.01% |
XEL | 37.43% | $38.97B | +28.76% | 3.31% |
PEP | 37.32% | $185.15B | -16.59% | 4.08% |
MRK | 36.60% | $204.32B | -35.44% | 3.88% |
AMRX | 36.59% | $2.59B | +21.15% | 0.00% |
POR | 36.50% | $4.46B | -4.57% | 4.96% |
LNT | 36.41% | $15.74B | +18.56% | 3.20% |
NVS | 36.32% | $230.90B | +12.43% | 3.27% |
ELS | 36.28% | $11.81B | -3.77% | 3.21% |
NSA | 35.83% | $2.46B | -19.84% | 7.03% |
Yahoo
BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases. On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and commercialization of BioNTech SE (NASDAQ:BNTX)’s […]
Yahoo
Bristol-Myers Squibb Company (NYSE:BMY) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater Associates holds over $142 million worth of shares of BMY, which represents 0.66% of its portfolio. On June 25, 2025, Bristol-Myers Squibb Company (NYSE:BMY) announced a new update regarding its plans for breast cancer treatments. […]
Yahoo
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
Yahoo
AZN's oncology sales rise 13% in Q1 2025, driven by key drugs and new approvals. Can this momentum last?
SeekingAlpha
Discover high-yield investment opportunities with the ReFa/Ro Dogs strategy! Analyst forecasts suggest 19-33% net gains by June 2026.
Yahoo
The schizophrenia market is projected to grow from USD 7.78 billion in 2024 to USD 13.67 billion by 2034, with a CAGR of 5.80%. Key growth drivers include rising schizophrenia prevalence, increased use of long-acting injectable antipsychotics, and advances in genetic and digital therapeutics. The U.S. leads in market share due to its robust healthcare system. Schizophrenia Market Schizophrenia Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Schizophrenia Market Report and Forecast 2025-203
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
GORV | <0.01% | $27.30M | -90.14% | 0.00% |
WNC | -0.02% | $472.29M | -45.43% | 2.84% |
QBTS | 0.03% | $5.00B | +1,327.68% | 0.00% |
MELI | 0.03% | $125.56B | +43.82% | 0.00% |
LUMN | 0.05% | $4.64B | +326.42% | 0.00% |
ULS | -0.07% | $14.26B | +63.55% | 0.72% |
SII | -0.09% | $1.77B | +60.87% | 1.69% |
GNE | 0.09% | $630.87M | +53.09% | 1.27% |
LQDA | -0.09% | $1.09B | +1.19% | 0.00% |
NXE | -0.13% | $3.75B | -3.80% | 0.00% |
DLR | -0.13% | $57.52B | +11.42% | 2.86% |
LQDT | -0.14% | $766.78M | +23.79% | 0.00% |
ANF | 0.15% | $4.14B | -51.47% | 0.00% |
DAO | -0.16% | $274.96M | +140.82% | 0.00% |
INTU | 0.17% | $217.99B | +20.15% | 0.51% |
MNOV | 0.17% | $61.31M | -8.76% | 0.00% |
NET | 0.18% | $66.83B | +133.48% | 0.00% |
BKSY | 0.19% | $712.81M | +178.71% | 0.00% |
TARS | 0.20% | $1.67B | +40.30% | 0.00% |
AQB | -0.20% | $3.01M | -53.91% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CLIP | -20.43% | $1.54B | 0.07% |
VIXY | -15.60% | $185.99M | 0.85% |
IVOL | -12.47% | $342.02M | 1.02% |
TAIL | -12.24% | $95.09M | 0.59% |
SOYB | -10.90% | $27.20M | 0.22% |
TPMN | -10.16% | $30.94M | 0.65% |
KCCA | -9.17% | $108.82M | 0.87% |
CANE | -8.15% | $11.26M | 0.29% |
ULST | -6.70% | $595.49M | 0.2% |
TFLO | -6.65% | $6.74B | 0.15% |
GOAU | -6.40% | $126.18M | 0.6% |
WEAT | -6.40% | $124.20M | 0.28% |
URNM | -6.12% | $1.73B | 0.75% |
DBA | -6.11% | $775.10M | 0.93% |
JMST | -6.08% | $4.08B | 0.18% |
QFLR | -5.76% | $297.20M | 0.89% |
SLVP | -5.60% | $322.25M | 0.39% |
SGOV | -5.60% | $50.43B | 0.09% |
GDX | -5.43% | $15.71B | 0.51% |
DBMF | -5.41% | $1.17B | 0.85% |
Double maintains 12 strategies that include BMY - Bristol Myers Squibb Co.